BlackRock Group’s BioCryst Pharmaceuticals BCRX Stock Holding History

BlackRock Group’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$164K	Buy	25,830 +2,300	+10%	+$12K	﹤0.01%	2714
2016 Q3	$104K	Buy	23,530 +984	+4%	+$3.93K	﹤0.01%	2811
2016 Q2	$64K	Sell	22,546 -328	-1%	-$1.02K	﹤0.01%	2880
2016 Q1	$65K	Buy	22,874 +9,345	+69%	+$41.4K	﹤0.01%	2868
2015 Q4	$140K	Sell	13,529 -440	-3%	-$4.38K	﹤0.01%	2598
2015 Q3	$159K	Sell	13,969 -142,588	-91%	-$1.9M	﹤0.01%	2582
2015 Q2	$2.34M	Buy	156,557 +11,554	+8%	+$131K	﹤0.01%	1464
2015 Q1	$1.31M	Buy	145,003 +1,808	+1%	+$18.7K	﹤0.01%	1718
2014 Q4	$1.74M	Buy	143,195 +1,900	+1%	+$21K	﹤0.01%	1552
2014 Q3	$1.38M	Buy	141,295 +1,095	+0.8%	+$13.4K	﹤0.01%	1594
2014 Q2	$1.79M	Buy	140,200 +119,443	+575%	+$1.16M	﹤0.01%	1521
2014 Q1	$220K	Buy	+20,757	New	+$221K	﹤0.01%	2453

Other funds holding BCRX

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BlackRock Group's BCRX Position: Q4 2016 in Review

BlackRock Group increased its BioCryst Pharmaceuticals (BCRX) stake by 9.8% in Q4 2016, buying an estimated $12K and bringing the position to 25,830 shares worth $164K. The position accounts for ﹤0.01% of the portfolio, ranked #2714.

BlackRock Group first reported a position in BCRX in Q1 2014 and has held it in 12 quarters since. The position peaked at $2.34M in Q2 2015. 112 funds tracked by Wall St. Rank hold BCRX as of Q4 2016.

BlackRock Group held 25,830 shares of BioCryst Pharmaceuticals worth $164K as of Q4 2016.
BlackRock Group bought 2,300 BioCryst Pharmaceuticals shares in Q4 2016, an estimated $12K.
BioCryst Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #2714 holding.
BlackRock Group first reported a position in BioCryst Pharmaceuticals in Q1 2014 and has held it in 12 quarters since.
BlackRock Group's BioCryst Pharmaceuticals position peaked at $2.34M in Q2 2015.
112 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.